key: cord-0691286-fmoasnyh authors: Kennedy, Vanessa E.; Wong, Chelsea C.; Hong, Jessica M.; Peng, Theodore; Brondfield, Sam; Reilly, Linda M.; Cornett, Patricia; Leavitt, Andrew D. title: VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis date: 2021-10-01 journal: Blood Adv DOI: 10.1182/bloodadvances.2021005388 sha: e63d2d8202eed8d93fbb7f8f0a8611852bd95f4d doc_id: 691286 cord_uid: fmoasnyh We report a case of vaccine-induced immune thrombotic thrombocytopenia (VITT) in a young man diagnosed 13 days after Ad26.COV2.S COVID-19 (Johnson & Johnson/Janssen) vaccination. He presented to us with five days of progressive left leg pain, thrombocytopenia, hypofibrinogenemia, and markedly elevated D-dimers, but without radiographically-demonstrable thrombosis. Despite negative imaging, we initiated treatment for presumptive VITT given the striking clinical picture that included the timing of his recent adenovirus-based COVID-19 vaccine, leg symptoms, marked thrombocytopenia, and consumptive coagulopathy. He received intravenous immune globulin (IVIG), prednisone, and argatroban and was discharged seven days later much improved. His positive Platelet Factor 4 (PF4) ELISA antibody test returned after treatment was initiated. To our knowledge, this is the first reported case of VITT following Ad26.COV2.S vaccination presenting without radiographically-demonstrable thrombosis. Our patient highlights the importance of knowing vaccine status and initiating treatment as soon as possible in the right clinical setting, even in the absence of radiographic evidence of thrombus. Early VITT recognition and treatment provides an opportunity to prevent serious thrombotic complications. hypofibrinogenemia, and markedly elevated D-dimers, but without radiographicallydemonstrable thrombosis. Despite negative imaging, we initiated treatment for presumptive VITT given the striking clinical picture that included the timing of his recent adenovirus-based COVID-19 vaccine, leg symptoms, marked thrombocytopenia, and consumptive coagulopathy. He received intravenous immune globulin (IVIG), prednisone, and argatroban and was discharged seven days later much improved. His positive Platelet Factor 4 (PF4) ELISA antibody test returned after treatment was initiated. To our knowledge, this is the first reported case of VITT following Ad26.COV2.S vaccination presenting without radiographically-demonstrable thrombosis. Our patient highlights the importance of knowing vaccine status and initiating treatment as soon as possible in the right clinical setting, even in the absence of radiographic evidence of thrombus. Early VITT recognition and treatment provides an opportunity to prevent serious thrombotic complications. A rare syndrome involving thrombosis and thrombocytopenia has been reported following COVID-19 vaccination with a recombinant adenoviral vector encoding the SARS-CoV-2 spike protein, including 41 reported cases following ChAdOx1 nCoV-19 (AstraZeneca) vaccination [1] [2] [3] [4] [5] and 28 cases following administration of over 8.7 million Ad26.COV2.S (Johnson & Johnson/Janssen) vaccinations in the United States. [6] [7] [8] Based on these reports, a new pathologic entity has been proposed, variably termed thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombotic thrombocytopenia (VITT). 9 The cases are notable for significant thrombocytopenia and anti-PF4 antibodies. 8, 9 In addition, exceedingly high D-dimer levels have been universally reported in VITT patients following ChAdOx1 nCoV-19 vaccination 1-3 and low fibrinogen levels are common, suggesting a coincident consumptive coagulopathy similar to severe autoimmune HIT. 12, 13 We present a case of VITT in a man who presented 13 days after receiving the Ad26.COV2.S vaccine without radiographically-demonstrable thrombosis who was successfully treated with intravenous immune globulin (IVIG), glucocorticoids, and non-heparin anticoagulation. Eight VITT was suspected given his vaccination history, symptoms, and laboratory findings. He was admitted and started on 1 g/kg of IVIG daily for two days to increase his platelet count and given 1 mg/kg of prednisone. The following day his pain worsened. Despite lack of radiographically-demonstrable thrombosis, anticoagulation with argatroban was started. Later that day, the enzyme-linked immunosorbent assay (ELISA) for anti-PF4 antibodies (Immucor, Norcross, GA, USA) drawn the day prior returned strongly positive at 2.79 optical-density (OD) units (normal, ≤ 0.40) in the absence of added heparin; the assay was negative in the presence of high-dose heparin (100 U/mL). The confirmatory washed-platelet heparin-induced platelet activation assay was positive. His platelets rose quickly in response to the IVIG (Fig. 1) , allowing us to start anticoagulation. Within 24 hours of starting argatroban, his pain began to improve. Given persistent venous distention, a repeat lower extremity ultrasound was performed that demonstrated reflux throughout the deep veins and the greater saphenous vein from the saphenofemoral junction to the mid-calf. The exam also identified non-occlusive thrombi in the left distal popliteal vein and peroneal vein, which were not present on admission. Over the next few days his platelets rose steadily, D-dimers fell precipitously, and he was transitioned from argatroban to apixaban (Fig. 1) . On the 6 th hospital day, repeat anti-PF4 ELISA The patient consented for this case report, which includes retrospective chart review and prospective data collection. The understanding of the clinical spectrum and natural history of VITT is evolving. 8, 9, 14 Given our patient's presenting history and exam, thrombocytopenia, markedly elevated D-dimers, and low fibrinogen, we initiated treatment for presumed VITT despite the absence of radiographically-demonstrable thrombosis and before his anti-PF4 ELISA resulted. To our knowledge, this is the first reported case of VITT following Ad26.COV2.S vaccination without radiographically-demonstrable thrombosis at presentation. Our patient's clinical course suggests that early VITT recognition and immediate treatment initiation provides a window of opportunity wherein non-heparin-based anticoagulation may prevent serious thrombotic complications. It also highlights the critical importance of knowing COVID-19 vaccine history, something that he was not asked when he first presented with leg symptoms and 'unexplained' thrombocytopenia. A recent report describes a woman who presented with petechiae 9 days after ChAdOx1 nCoV-19 vaccination and was found to have thrombocytopenia, hypofibrinogenemia, markedly elevated D-dimer, but no demonstrable thrombosis at presentation. She was treated with IVIG and non-heparin anticoagulation and was discharged without known thrombosis development, but repeat imaging was not reported. 4 That case and ours demonstrate that there is a window wherein early treatment can prevent serious VITT complications. We suggest that patients who present with thrombocytopenia and markedly elevated D-dimers 5-30 days following adenovirus-based COVID-19 vaccination receive nonheparin anticoagulation independent of radiographically-demonstrable thrombosis and pending anti-PF-4 ELISA results. On the day of presentation, our patient's anti-PF4 ELISA and the confirmatory platelet activation assay were positive. Five, 13, and 43 days later, the anti-PF4 ELISA remined strongly positive, but the confirmatory platelet activation assay was negative, the latter likely due to the impact of IVIG on the platelet activation assay 15, 16 . It will be important to define the time course for positive anti-PF4 antibodies in patients with VITT, and to understand risk of long-term thrombosis, spontaneous recurrence, and safety of future heparin or adenovirus-based vaccine exposure. VITT remains a rare complication. However, given the large number of people anticipated to receive adenovirus-based COVID-19 vaccination, it is critical that clinicians recognize the presenting clinical spectrum of this emerging syndrome. We need to anticipate that VITT will have various presentations, much like HIT itself. 17 The diagnostic criteria for VITT will need continued refinement, including criteria that support early intervention. Timely recognition will be essential to prevent catastrophic complications and will require knowing the patient's vaccine history. For original data, please contact vanessa.kennedy@ucsf.edu. is the maximum D-dimer value reported by our laboratory. Hospitalization, the gray shaded column, indicates the time from presentation to our emergency department until discharge from the hospital. IVIG (1 gm/kg) was administered to increase platelet count to allow for safe initiation of anticoagulation. Cryoprecipitate (1st dose 10 units; 2 nd dose 5 units) was given to improve fibrinogen levels to allow for safe initiation of anticoagulation. Prednisone 1mg/kg/day with taper. Therapeutic argatroban was dosed for target aPTT of 60-80 seconds. Apixaban 10 mg twice daily x 7 days followed by 5 mg twice daily. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination Update: Thrombosis with thrombocytopenia syndrome (TTS) following COVID-19 vaccination Thrombosis with Thrombocytopenia Syndrome (also termed Vaccine-induced Thrombotic Thrombocytopenia). Version 1.2, last updated Centers for Disease Control and Prevention (CDC): Press Release. FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVD-19 Vaccine Use Following Thorough Safety Review Vaccine Safety Technical (VaST) Work Group Advisory Committee on Immunization Practices Autoimmune heparin-induced thrombocytopenia SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia Recommendations for the clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia (VITT) for SARS-CoV-2 infections: Communication from the ISTH SSC Subcommittee on Platelet Immunology Intravenous Immune Globulin to Prevent Heparin-Induced Thrombocytopenia High-dose intravenous immunoglobulin to treat spontaneous heparin-induced thrombocytopenia syndrome Laboratory diagnosis of heparin-induced thrombocytopenia The authors thank Agnes Y. Y. Lee, University of British Columbia, for critical reading of the manuscript. Contribution: VK, CW, PC, and AL provided concept and design; VK, CW, JH, TP, and SB acquired data, including patient management; VK, CW, SB, PC, AL wrote and revised manuscript; LR provided expert interpretation of the vascular ultrasound. The authors declare no competing financial interests.